血友病凝血因子浓缩物群体药代动力学模型:综述与最佳实践评估
本文综述了已发表的凝血因子VIII和IX浓缩物的群体药代动力学模型,收集了其使用的人口学、产品类型、协变量、实验室规格及模型验证等数据,并按最佳实践建议对模型的数据记录质量进行评分。共检索到20个FVIII模型和7个FIX模型,发现多数模型纳入儿童患者但仅少数报告详细人口学数据,且实验室试剂记录不全。作者提出了数据收集和记录的建议,以提高PK指导预防治疗的可靠性。
要点
- 已发表FVIII群体PK模型20个、FIX模型7个,多数纳入儿童但仅4个报告详细人口学。
- 仅16个模型报告了测量因子水平所用试剂,8个模型进行了内部验证。
- 模型数据记录质量参差不齐,需按建议规范数据收集以提高PK指导给药可靠性。
核心结论
- 已发表的FVIII和FIX群体PK模型在数据记录方面存在不足,需规范数据收集与记录以提高PK指导预防治疗的可靠性。
研究设计与样本
- 文献综述:检索描述基于原始患者数据、采用非线性混合效应模型构建的FVIII和FIX浓缩物预防性群体PK模型的出版物。
主要发现
- 共检索到20个FVIII模型和7个FIX模型,其中22/27纳入了儿童患者,但仅4个报告了详细人口学数据。
- 8个模型使用数据子集进行了内部验证。
关键数值与推荐
- 按作者提出的最佳实践建议对纳入模型的数据记录质量进行评分,具体评分依据为所报告的数据记录质量。
临床怎么用
- 医生在选择PK模型时应关注模型构建所用的临床和实验室数据质量及患者个体PK特征,并参照建议规范数据收集与记录。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The accuracy of pharmacokinetic (PK)-guided dosing depends on the clinical and laboratory data used to construct a population PK model, as well as the patient's individual PK profile. This review provides a detailed overview of data used for published population PK models for factor VIII (FVIII) and factor IX (FIX) concentrates, to support physicians in their choices of which model best suits each patient. Furthermore, to enhance detailed data collection and documentation, we do suggestions for best practice. A literature search was performed; publications describing prophylactic population PK models for FVIII and FIX concentrates based on original patient data and constructed using nonlinear mixed-effect modeling were included. The following data were collected: detailed demographics, type of product, assessed and included covariates, laboratory specifications, and validation of models. Included models were scored according to our recommendations for best practice, specifically scoring the quality of data documentation as reported. Respectively, 20 models for FVIII and 7 for FIX concentrates were retrieved. Although most models (22/27) included pediatric patients, only 4 reported detailed demographics. The wide range of body weights suggested that overweight and obese adults were represented. Twenty-six models reported the assay applied to measure factor levels, whereas only 16 models named reagents used. Eight models were internally validated using a data subset. This overview presents detailed information on clinical and laboratory data used for published population PK models. We provide recommendations on data collection and documentation to increase the reliability of PK-guided prophylactic dosing of factor concentrates in hemophilia A and B.
引用
- Goedhart TMHJ, Bukkems LH, Zwaan CM, et al. Population pharmacokinetic modeling of factor concentrates in hemophilia: an overview and evaluation of best practice. Blood Adv. 2021. PMID: 34496017. doi:10.1182/bloodadvances.2021005096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。